NCT00468923View on ClinicalTrials.gov

Heart Outcomes Prevention Evaluation-3

PHASE4CompletedINTERVENTIONAL
Enrollment

12,705

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

December 31, 2015

Study Completion Date

January 31, 2016

Conditions
Cardiovascular DiseaseStroke
Interventions
DRUG

Candesartan/HCT

Candesartan 16 mg/HCT 12.5 once daily

DRUG

Rosuvastatin

Rosuvastatin 10 mg once daily

Trial Locations (1)

L8L 2X2

Hamilton General Hospital, Hamilton

Sponsors
All Listed Sponsors
lead

Population Health Research Institute

OTHER